Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded Unicycive Therapeutics from “strong sell” to “hold.” Despite mixed analyst actions, the stock carries a “Moderate Buy” consensus rating and an average price target of $18.75.
• UNCY opened at $5.45 and was trading below its 50-day and 200-day moving averages, with a 12-month range of $3.71 to $8.74. The company reported a quarterly loss of $0.06 per share, beating estimates for a $0.47 loss.
• Institutional ownership stands at 40.42%, with several investors—including JPMorgan Chase and Bank of America—recently increasing or initiating positions. Unicycive is developing kidney-disease treatments, including Renazorb and the Phase 1 therapy UNI 494.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) was upgraded by equities researchers at Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on UNCY. Benchmark reissued a "speculative buy" rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday. B. Riley Financial reaffirmed a "buy" rating and set a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Unicycive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. HC Wainwright cut their price objective on Unicycive Therapeutics from $22.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, June 30th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.75.

Unicycive Therapeutics Trading Down 2.3%

NASDAQ UNCY opened at $5.45 on Wednesday. The business's 50-day moving average price is $5.80 and its 200 day moving average price is $6.61. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $8.74. The company has a market capitalization of $151.78 million, a PE ratio of -3.11 and a beta of 1.79.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.41. Equities analysts predict that Unicycive Therapeutics will post -1.17 EPS for the current year.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in shares of Unicycive Therapeutics during the second quarter worth about $55,000. JPMorgan Chase & Co. grew its stake in shares of Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock valued at $104,000 after buying an additional 21,525 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Unicycive Therapeutics during the 1st quarter valued at about $161,000. Citadel Advisors LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter worth approximately $182,000. Finally, Bank of America Corp DE boosted its holdings in Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock worth $194,000 after acquiring an additional 29,378 shares during the period. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source